Quinolone activity against anaerobes
- PMID: 10553708
- DOI: 10.2165/00003495-199958002-00012
Quinolone activity against anaerobes
Abstract
The first generation of fluoroquinolones such as ciprofloxacin and ofloxacin are inactive against most anaerobic bacteria. However, some broad-spectrum quinolones, which have recently become clinically available or are under active development, have significant antianaerobic activity. This review summarises the in vitro activity of currently available, as well as experimental, quinolones against clinically significant anaerobic bacteria. Quinolones with low activity against anaerobes include ciprofloxacin, ofloxacin, levofloxacin, fleroxacin, pefloxacin, enoxacin and lomefloxacin. Compounds with intermediate antianaerobic activity include sparfloxacin and grepafloxacin. Trovafloxacin, gatifloxacin and moxifloxacin yield low MICs against most groups of anaerobes. Quinolones with the greatest in vitro activity against anaerobes include clinafloxacin and sitafloxacin (DU-6859a).
Similar articles
-
Quinolone activity against anaerobes: microbiological aspects.Drugs. 1995;49 Suppl 2:76-80. doi: 10.2165/00003495-199500492-00012. Drugs. 1995. PMID: 8549420 Review.
-
In vitro susceptibility of anaerobes to quinolones in the United States.Clin Infect Dis. 1996 Dec;23 Suppl 1:S2-8. doi: 10.1093/clinids/23.supplement_1.s2. Clin Infect Dis. 1996. PMID: 8953099
-
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.Clin Infect Dis. 1996 Dec;23 Suppl 1:S25-30. doi: 10.1093/clinids/23.supplement_1.s25. Clin Infect Dis. 1996. PMID: 8953103 Review.
-
Effect of quinolones on intestinal ecology.Drugs. 1999;58 Suppl 2:65-70. doi: 10.2165/00003495-199958002-00013. Drugs. 1999. PMID: 10553709 Review.
-
[Quinolones: historic review].Medicina (B Aires). 1999;59 Suppl 1:3-7. Medicina (B Aires). 1999. PMID: 10436548 Spanish.
Cited by
-
Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.Antimicrob Agents Chemother. 2013 Jun;57(6):2705-11. doi: 10.1128/AAC.02289-12. Epub 2013 Apr 1. Antimicrob Agents Chemother. 2013. PMID: 23545524 Free PMC article.
-
Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.Molecules. 2021 Nov 25;26(23):7153. doi: 10.3390/molecules26237153. Molecules. 2021. PMID: 34885734 Free PMC article. Review.
-
Gatifloxacin: a review of its use in the management of bacterial infections.Drugs. 2002;62(1):169-207. doi: 10.2165/00003495-200262010-00007. Drugs. 2002. PMID: 11790160 Review.
-
Global fluoroquinolone resistance epidemiology and implictions for clinical use.Interdiscip Perspect Infect Dis. 2012;2012:976273. doi: 10.1155/2012/976273. Epub 2012 Oct 14. Interdiscip Perspect Infect Dis. 2012. PMID: 23097666 Free PMC article.
-
Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.Antimicrob Agents Chemother. 2003 Jul;47(7):2256-63. doi: 10.1128/AAC.47.7.2256-2263.2003. Antimicrob Agents Chemother. 2003. PMID: 12821477 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources